Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Bridging Study of BW-20805-2 in Healthy Participants
NCT07528053Phase 1Not yet recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of BW-20805-2 (3 cohorts), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
BW-20805-2
Beyond the preview
Go deeper on NCT07528053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528053.